Alpha-blockade therapy for benign prostatic hyperplasia:: From a nonselective to a more selective alpha1A-adrenergic antagonist

被引:64
作者
Beduschi, MC [1 ]
Beduschi, R [1 ]
Oesterling, JE [1 ]
机构
[1] Univ Michigan, Urol Sect, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/S0090-4295(98)00140-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Benign prostatic hyperplasia (BPH) is very common in older men, causing symptoms that can markedly impair quality of life. Surgical treatment, typically transurethral resection of the prostate (TURP), is highly effective but can be costly and is associated with the risk for significant morbidity. Medical treatments for BPH are targeted toward reducing bladder outlet obstruction either by androgen blockade to reduce prostatic volume or alpha-adrenergic blockade to relax the smooth muscle tone of the prostate. In recent years, understanding of the sympathetic innervation of the prostate has improved. This has been paralleled by the development of alpha-adrenergic blocking agents, from nonselective alpha-antagonists, to selective alpha(1)-antagonists, to the more selective alpha(1A)-antagonists. It is anticipated that more specific agents will optimize the therapeutic effectiveness of alpha-adrenergic blockade in the prostate while reducing the side effects associated with alpha-adrenergic blockade in other areas of the body, such as the vascular system. This article reviews the evolution of alpha-blockade therapy in management of BPH, focusing on tamsulosin, an agent targeted toward the alpha(1A)-adrenoceptor that predominates in the prostate. Clinical trials in Europe and the United States have provided evidence that tamsulosin is effective at doses of 0.4 and 0.8 mg/day. At both doses, tamsulosin is associated with significant improvements in the American Urological Association symptom score and the mean and peak urinary flow rates as compared with placebo. This once-daily alpha(1A)-adrenergic antagonist is well-tolerated, with a minimal potential for the side effects associated with alpha(1)-blocker therapy. (C) 1998, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:861 / 872
页数:12
相关论文
共 49 条
[1]   BLADDER OUTFLOW OBSTRUCTION TREATED WITH PHENOXYBENZAMINE [J].
ABRAMS, PH ;
SHAH, PJR ;
STONE, R ;
CHOA, RG .
BRITISH JOURNAL OF UROLOGY, 1982, 54 (05) :527-530
[2]  
[Anonymous], AHCPR PUBLICATION
[3]   LIGHT MICROSCOPIC STEREOLOGICAL ANALYSIS OF THE NORMAL HUMAN-PROSTATE AND OF BENIGN PROSTATIC HYPERPLASIA [J].
BARTSCH, G ;
MULLER, HR ;
OBERHOLZER, M ;
ROHR, HP .
JOURNAL OF UROLOGY, 1979, 122 (04) :487-491
[4]  
Brawer M K, 1993, Arch Fam Med, V2, P929, DOI 10.1001/archfami.2.9.929
[5]   MOLECULAR-CLONING AND SEQUENCING OF A CDNA-ENCODING A HUMAN ALPHA(1A) ADRENERGIC-RECEPTOR [J].
BRUNO, JF ;
WHITTAKER, J ;
SONG, JF ;
BERELOWITZ, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 179 (03) :1485-1490
[6]  
BRUSKEWITZ RC, 1992, HOSP PRACT, V27, P99
[7]   PLACEBO-CONTROLLED DOUBLE-BLIND-STUDY OF EFFECT OF PHENOXYBENZAMINE IN BENIGN PROSTATIC OBSTRUCTION [J].
CAINE, M ;
PERLBERG, S ;
MERETYK, S .
BRITISH JOURNAL OF UROLOGY, 1978, 50 (07) :551-554
[8]   PHENOXYBENZAMINE FOR BENIGN PROSTATIC OBSTRUCTION - REVIEW OF 200 CASES [J].
CAINE, M ;
PERLBERG, S ;
SHAPIRO, A .
UROLOGY, 1981, 17 (06) :542-546
[9]  
CAINE M, 1976, BRIT J UROL, V48, P255, DOI 10.1111/j.1464-410X.1976.tb03013.x
[10]  
CARTER HB, 1990, PROSTATE, V16, P39